

A

ABBI Device, *see* Advanced Breast Biopsy Instrumentation Device
Advanced Breast Biopsy Instrumentation (ABBI) Device, advantages, 71
sample collection, 70

B

Brain tumor, *see* Magnetic resonance imaging, brain
Breast cancer,
Advanced Breast Biopsy Instrumentation Device, advantages, 71
sample collection, 70
directional vacuum-assisted biopsy probes, accuracy, 69
advantages, 68, 69
calcification retrieval rate, 69
ultrasound guidance, 69
fine-needle aspiration biopsy, accuracy and specificity, 57–60
mammographic guidance, 59
ultrasound guidance, 59, 60
fluorescent probes imaging, 263
follow-up after biopsy, 71
large-core needle biopsy, accuracy and specificity, 60, 61
atypical ductal hyperplasia, 66, 67
automated core needles, 61, 63
ductal carcinoma *in situ*, 66, 67
stereotactic imaging, 63, 68
ultrasound guidance, 66–68
magnetic resonance imaging, *see* Magnetic resonance imaging, breast

mammographic wire localization for excisional surgery biopsy, 53–55
mortality trends, 53
preoperative chemotherapy, clinical examination, 214
magnetic resonance imaging, 219, 222, 223, 226
mammography, 218
positron emission tomography, 219
rationale, 213, 214
tumor volume measurements, 215
ultrasound, 218
screening, 53, 94, 96, 97
ultrasound wire localization for excisional surgery biopsy, 55, 56

C

Computed tomography (CT), three-dimensional conformal radiation therapy, 202, 203
CT, *see* Computed tomography

D

Directional vacuum-assisted (DVA) biopsy probes, breast, accuracy, 69
advantages, 68, 69
calcification retrieval rate, 69
ultrasound guidance, 69
DVA biopsy probes, *see* Directional vacuum-assisted biopsy probes, breast

F

Fine-needle aspiration biopsy (FNAB), breast, accuracy and specificity, 57–60
mammographic guidance, 59

- intraoperative imaging,
 - complication detection, 105
 - development, 101, 181, 182
 - frameless stereotactic navigation, 107, 108, 113, 181, 183, 184
 - inaccuracy sources, 184
 - multimodal fusion imaging, 108, 109, 111, 188
 - stereotactic frames, 181, 182
 - systems,
 - Brigham and Women's Hospital system, 109, 110, 112, 113, 185, 186
 - Magnetom OPEN scanner, 186
 - PoleStar system, 187, 188
 - University of Minnesota system, 186, 187
- low-grade gliomas, 101
- prospects, 190
- radiation-induced changes, 102, 103
- skull base tumors, 170, 172
- spectroscopy of tumors, 103, 104, 176, 178, 204
- stereotactic radiosurgery, 189, 190
- suprasellar tumors, 172
- Magnetic resonance imaging, breast,
 - adjunctive imaging test, 87, 91
 - biopsy guidance, 78, 82
 - coils, 76, 77
 - contrast-enhanced imaging,
 - fat signal suppression, 77, 78
 - injection of contrast agent, 77
 - spatial and temporal resolution, 77
 - interpretation of images, 82, 85, 86
 - magnetic field strength, 76
 - preoperative chemotherapy
 - evaluation, 215, 219, 222, 223, 226
 - prospects, 98
 - screening for cancer, 94, 96, 97
 - sensitivity of cancer detection, 75, 76
 - staging of cancer, 92, 94
- Magnetic resonance imaging-guided prostate biopsy,
 - contrast agents, 41
 - development, 42, 43
 - diffusion imaging, 39, 41
 - imaging, 44
 - indications, 43
 - patient preparation, 43
 - prostate zonal anatomy, 37
 - proton spectroscopy, 38
 - sextant sampling, 44
 - T2 mapping, 38, 39
- Magnetic resonance imaging-guided prostate brachytherapy,
 - advantages, 156
 - development, 41, 42
 - dosimetry, 159
 - geometric and dosimetric feedback, 159
 - image acquisition, 44, 45
 - image analysis,
 - registration, 46, 48–50
 - segmentation, 45, 46, 48, 49
 - three-dimensional visualization, 46
 - instrumentation, 44
 - instrumentation, 158
 - medical management, 158
 - outcomes,
 - acute morbidity, 161
 - dose volume histogram analysis, 161
 - patient positioning, 158
 - patient selection, 156, 157
 - postoperative instructions, 159, 161
 - predictive factors, 162
 - preoperative assessment, 157
 - preoperative imaging, 158, 159
 - prospects, 164
 - prostate-specific antigen levels, 162–164
 - quality-of-life, 161, 162
 - software, 42
- Magnetic resonance spectroscopy (MRS), brain tumors, 103, 104, 176, 178, 204, 205
- Magnetic resonance thermometry, 238
- Mammogram, *see* Breast cancer
- MRI, *see* Magnetic resonance imaging
- MRS, *see* Magnetic resonance spectroscopy

N

Near infrared fluorochrome probes, *see*
Fluorescent probes, cancer imaging

P

PET, *see* Positron emission tomography
Positron emission tomography (PET),
preoperative chemotherapy evaluation
of breast cancer evaluation, 219
three-dimensional conformal radiation
therapy, 205, 206

Prostate cancer,

biopsy, *see* Magnetic resonance
imaging-guided prostate biopsy;
Transrectal ultrasound-guided
prostate biopsy

brachytherapy, *see* Magnetic
resonance imaging-guided
prostate brachytherapy;
Transrectal ultrasound-guided
prostate brachytherapy

central zone, 3, 4, 7, 37

epidemiology, 3, 35, 155

fall-off effect, 155

peripheral zone, 3, 4, 7, 37

thermal therapy, *see* Image-guided
thermal therapy, prostate cancer

transition zone, 3, 4, 7, 25

treatment approaches, 119, 229

Prostate-specific antigen (PSA),

age-adjusted levels, 5

magnetic resonance imaging-guided
prostate brachytherapy
outcomes, 162–164

screening, 119, 229

transrectal ultrasound-guided prostate
biopsy indications, 4

PSA, *see* Prostate-specific antigen

R

Radiation therapy, *see* Three-
dimensional conformal
radiation therapy

Radiosurgery, magnetic resonance
imaging in planning, 189, 190

S

Spine, magnetic resonance imaging
of tumors, 172

T

Thermal ablation, *see* Hyperthermia

Three-dimensional conformal radiation
therapy,

biological target volumes, 207

clinical target volume, 207

computed tomography, 202, 203

delivery, 201

gross target volume, 207

magnetic resonance imaging, 203

molecular imaging, 206

planning target volume, 207

positron emission tomography,
205, 206

TIPPB, *see* Transperineal interstitial
permanent prostate
brachytherapy

Transperineal interstitial permanent
prostate brachytherapy (TIPPB),
see Transrectal ultrasound-
guided prostate brachytherapy

Transrectal ultrasound (TRUS)-guided
prostate biopsy,
accuracy and specificity, 7, 9, 35
advantages over standard sextant
biopsy, 3

anesthesia,

clinical trials, 14

intrarectal lidocaine gel, 13, 15

pain causes, 11, 12

periprostatic anesthesia, 13, 15

color Doppler imaging, 9–11

complications, 11

contrast agent use, 10, 11

hypoechoic prostate areas, 8, 9

indications, 4

needle biopsy,

computer models for optimization,
17, 18, 21, 22

core number and cancer detection,
24, 35

- eight-region systematic biopsy
 - template, 23
 - eleven-core multisite-directed biopsy template, 23
 - extensive biopsy protocols, 18–21, 24
 - five-region systematic biopsy template, 22
 - repeat biopsy, 24, 25
 - sample collection, 11
 - sextant biopsy template, 16
 - transition zone biopsy, 25–27
 - patient preparation, 5, 6
 - power Doppler imaging, 10
 - prostate size impact on detection, 27, 28
 - prostate zonal anatomy, 3, 4, 7, 21, 22
 - sonographic imaging of prostate cancers, 10
 - technique, 6, 7
 - Transrectal ultrasound (TRUS)-guided prostate brachytherapy, historical perspective, 119–121
 - transperineal interstitial permanent prostate brachytherapy, demand, 119
 - development, 121–123
 - doses and isotopes, 131, 132
 - implant procedure, 132–136
 - outcomes, 143–145, 147, 155
 - patient selection, 123–126
 - planning, 126, 127
 - postoperative dosimetric evaluation, 137–140
 - principles, 119
 - prospects, 147
 - target volume determination, 129–131
 - toxicity, 140–143, 155
 - volume study, 127–129
 - Transrectal ultrasound (TRUS)-guided thermal therapy, prostate cancer, 234–236
 - TRUS, *see* Transrectal ultrasound
- ## U
- Ultrasound,
 - breast cancer biopsy, *see* Breast cancer
 - high-intensity focused ultrasound therapy, *see* Image-guided thermal therapy, prostate cancer
 - transrectal, *see* Transrectal ultrasound